Citi initiated coverage of ResMed’s (RMD) U.S. shares with a Buy rating and $330 price target The firm believes the company’s gross margin expansion potential over the next few years is being underestimated in consensus estimates. Citi sees upside to ResMed’s fiscal 2027 estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: